Терапевтический архив (Aug 2018)

Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program “odyssey”

  • I V Maev,
  • Yu A Kucheravy,
  • V V Tsukanov,
  • E Yu Eremnia,
  • D N Andreev,
  • S R Abdulhakov,
  • V A Akhmedov,
  • S S Batskov,
  • A V Vasyutin,
  • E S V’yuchnova,
  • D N Ivanchenko,
  • E V Luzina,
  • O V Krapivnaya,
  • E V Onuchina,
  • M F Osipenko,
  • V I Simanenkov,
  • Yu L Tonkih,
  • N M Khomeriki,
  • A E Shklyaev,
  • A V Akimov,
  • K A Sokolov

DOI
https://doi.org/10.26442/terarkh201890840-47
Journal volume & issue
Vol. 90, no. 8
pp. 40 – 47

Abstract

Read online

Aim: to assess the effectiveness of mebeverine 200 mg BID in patients with post-cholecystectomy gastrointestinal spasm not requiring surgical treatment. Materials and methods. 218 patients were included in 16 clinical centers in 14 cities in Russia. All patients had post-cholecystectomy gastrointestinal spasms, not requiring surgical treatment and received mebeverine (Duspatalin®) 200 mg BID. The observational assessment period lasted from the moment of their inclusion into the study up to 6 weeks post inlusion. The therapy results were evaluated using visual analog scales (GPA and 11-point numeric rating scale) by patient self-assessment of the dynamics of spasm/discomfort and other post-cholecystectomic gastrointestinal symptoms after 2 and 6 weeks of treatment. Gastrointestinal Quality of Life Index (GIQLI) was used to assess patient quality of life. Results and discussion. All 218 patients completed the 2-week mebeverine treatment course, 101 of them finished the 6-week course (“prolonged population”). Significant positive changes in the relief of abdominal pain and dyspepsia were noted as well as normalization of stool frequency and consistency. A more marked change in values was observed during prolonged (up to 6 weeks) therapy. Both 2-week and 6-week mebeverine courses led to a normalization of patient quality of life. After 6 week therapy, an effect of mebeverine on the quality of life 91% of patients was observed comparable to cholecystectomy itself, speficially related to the quality of life subscore ‘symptoms’. Conclusion. The results of our study demonstrate that mebeverine (Duspatalin®) therapy leads to an effective elimination of clinical symptoms associated with post-cholecystectomy GI-spasm disorders, like abdominal pain, symptoms of dyspepsia and stooldisorders. A more marked change in values was observed during prolonged (up to 6 weeks) therapy.

Keywords